智飞生物青少年及成人组分百白破疫苗临床试验获批

Core Viewpoint - Zhifei Biological's subsidiary has received approval for clinical trials of a new vaccine aimed at preventing infectious diseases caused by diphtheria, tetanus, and whooping cough [1] Group 1 - Zhifei Biological announced that its wholly-owned subsidiary, Beijing Zhifei Lvzhu Biological Pharmaceutical Co., Ltd., has obtained the clinical trial approval notice from the National Medical Products Administration [1] - The vaccine is an adsorbed acellular diphtheria, tetanus, and pertussis (DTPa) combined vaccine intended for adults and adolescents [1] - The clinical trials will focus on preventing infections caused by diphtheria, tetanus, and whooping cough [1]